Similar articles for PMID: 28935836

Year	Number of Results
1960	1
1990	1
1999	1
2000	1
2001	4
2002	3
2003	1
2004	3
2005	5
2006	1
2007	6
2008	1
2009	2
2010	8
2011	14
2012	8
2013	1
2014	3
2015	7
2016	3
2017	12
2018	10
2019	4
2020	1
2024	0

1

Fendler WP, Cutler C. Fendler WP, et al. J Nucl Med. 2017 Nov;58(11):1709-1710. doi: 10.2967/jnumed.117.198333. Epub 2017 Sep 21. J Nucl Med. 2017. PMID: 28935836 Free article. No abstract available.

2

The best radionuclide for radioimmunotherapy of small tumors: beta- or alpha-emitter?

Barbet J, Chatal JF. Barbet J, et al. Eur J Nucl Med Mol Imaging. 2011 Feb;38(2):271-3. doi: 10.1007/s00259-010-1707-7. Eur J Nucl Med Mol Imaging. 2011. PMID: 21161707 No abstract available.

3

Alpha- versus beta-particle radiopeptide therapy in a human prostate cancer model (213Bi-DOTA-PESIN and 213Bi-AMBA versus 177Lu-DOTA-PESIN).

Wild D, Frischknecht M, Zhang H, Morgenstern A, Bruchertseifer F, Boisclair J, Provencher-Bolliger A, Reubi JC, Maecke HR. Wild D, et al. Cancer Res. 2011 Feb 1;71(3):1009-18. doi: 10.1158/0008-5472.CAN-10-1186. Epub 2011 Jan 18. Cancer Res. 2011. PMID: 21245097 Free article.

4

Dose escalation improves cancer-related events at 10 years for intermediate- and high-risk prostate cancer patients treated with hypofractionated high-dose-rate boost and external beam radiotherapy.

Martinez AA, Gonzalez J, Ye H, Ghilezan M, Shetty S, Kernen K, Gustafson G, Krauss D, Vicini F, Kestin L. Martinez AA, et al. Int J Radiat Oncol Biol Phys. 2011 Feb 1;79(2):363-70. doi: 10.1016/j.ijrobp.2009.10.035. Int J Radiat Oncol Biol Phys. 2011. PMID: 21195875 Clinical Trial.

5

The Future of Radioligand Therapy: α, β, or Both?

Haberkorn U, Giesel F, Morgenstern A, Kratochwil C. Haberkorn U, et al. J Nucl Med. 2017 Jul;58(7):1017-1018. doi: 10.2967/jnumed.117.190124. Epub 2017 Apr 13. J Nucl Med. 2017. PMID: 28408527 Free article. No abstract available.

6

Clinical estimation of α/β values for prostate cancer from isoeffective phase III randomized trials with moderately hypofractionated radiotherapy.

Datta NR, Stutz E, Rogers S, Bodis S. Datta NR, et al. Acta Oncol. 2018 Jul;57(7):883-894. doi: 10.1080/0284186X.2018.1433874. Epub 2018 Feb 6. Acta Oncol. 2018. PMID: 29405785

7

Comments on "Comparison of in vitro and in vivo alpha/beta ratios for prostate cancer".

Daşu A, Fowler JF. Daşu A, et al. Phys Med Biol. 2005 Mar 21;50(6):L1-4; author reply L5-8. doi: 10.1088/0031-9155/50/6/l01. Phys Med Biol. 2005. PMID: 17001787 No abstract available.

8

Radiosensitivity of Prostate Cancer Cell Lines for Irradiation from Beta Particle-emitting Radionuclide ¹⁷⁷Lu Compared to Alpha Particles and Gamma Rays.

Elgqvist J, Timmermand OV, Larsson E, Strand SE. Elgqvist J, et al. Anticancer Res. 2016 Jan;36(1):103-9. Anticancer Res. 2016. PMID: 26722033

9

Therapeutic Radiometals Beyond ¹⁷⁷Lu and ⁹⁰Y: Production and Application of Promising α-Particle, β^--Particle, and Auger Electron Emitters.

Müller C, van der Meulen NP, Benešová M, Schibli R. Müller C, et al. J Nucl Med. 2017 Sep;58(Suppl 2):91S-96S. doi: 10.2967/jnumed.116.186825. J Nucl Med. 2017. PMID: 28864619 Free article. Review.

10

[Principles, modalities and indications of the administration of Radium in cancers, focus on metastatic prostate cancer: State of arts].

Bertolaso P, Leroy L, Gross-Goupil M, Aupee O, Ravaud A, Roubaud G, Cazeau AL, Le Moulec S. Bertolaso P, et al. Bull Cancer. 2017 Sep;104(9):762-770. doi: 10.1016/j.bulcan.2017.06.011. Epub 2017 Aug 7. Bull Cancer. 2017. PMID: 28797482 Review. French.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

91 results

Results by year